References
- Yuantao HOU, Lu LIU, Changlin WANG. Advances in immunotherapy of
neuroblastoma. Clinical J Pediatric Surg. 2011; 10(4): 290-293. doi:
10.3969/j.issn.1671-6353.2011.04.020
- Heczey
A,
Louis
CU. Advances in
chimeric antigen receptor immunotherapy for neuroblastoma.
Discov Med. 2013; 16(90):
287-294. PMCID:
PMC4106238
- Seeger RC. Immunology and Immunotherapy of Neuroblastoma. Semin Cancer
Biol. 2011; 21(4): 229-237. doi: 10.1016/j.semcancer.2011.09.012.
- Pistoia V, Morandi F, Bianchi G, Pezzolo A, Prigione I, Raffaghello L.
Immunosuppressive
microenvironment in neuroblastoma. Front Oncol. 2013; 3:
167(1-8). doi: 10.3389/fonc.2013.00167.
- Tilak T, Sherawat S, Agarwala S,
Gupta
R,
Vishnubhatla
S,
Bakhshi
S. Circulating
T-regulatory cells in neuroblastoma: a pilot prospective study.
Pediatr Hematol Oncol. 2014; 31(8): 717-722. doi:
10.3109/08880018.2014.886002.
- Long AH, Highfill SL, Cui Y,
Smith
JP,
Walker
AJ,
Ramakrishna
S,
El-Etriby
R,
Galli
S,
Tsokos
MG,
Orentas
RJ,
et
al. Reduction of
MDSCs with all-trans retinoic acid improves CAR therapy efficacy for
sarcomas. Cancer Immunol Res. 2016; 4(10): 869-880. doi:
10.1158/2326-6066.CIR-15-0230.
- Komohara Y, Takeya M.
CAFs and TAMs:
maestros of the tumour microenvironment. J Pathol. 2017; 241(3):
313-315. doi: 10.1002/path.4824.
- Hashimoto O, Yoshida M, Koma Y,
Yanai
T,
Hasegawa
D,
Kosaka
Y, Nishimura
N, Yokozaki H.
Collaboration of
cancer-associated fibroblasts and tumour-associated macrophages
forneuroblastoma development. J Pathol. 2016; 240(2): 211-223. doi:
10.1002/path.4769.
- Matthay
KK, Maris
JM, Schleiermacher
G, Nakagawara A, Mackall
CL, Diller
L, Weiss
WA.
Neuroblastoma.
Nat Rev Dis Primers. 2016;
2: 16078. doi: 10.1038/nrdp.2016.78.
- Jales
A, Falahati
R, Mari
E,
Stemmy
EJ,
Shen
W,
Southammakosane
C,
Herzog
D,
Ladisch
S,
Leitenberg
D. Ganglioside-exposed dendritic cells inhibit T-cell effector
function by promoting regulatory cell activity.
Immunology. 2011;
132(1): 134-143. doi: 10.1111/j.1365-2567.2010.03348.x.
- Nagaraj S, Schrum AG, Cho HI, Celis E, Gabrilovich DI. Mechanism of T
cell tolerance induced by myeloid-derived suppressor cells. J Immunol.
2010; 184(6): 3106-3116. doi: 10.4049/jimmunol.0902661.
- Hanson
EM, Clements
VK, Sinha P, Ilkovitch D, Ostrand-Rosenberg S. Myeloid-derived
suppressor cells down-regulate L-selectin expression on CD4+ and CD8+
Tcells.
J
Immunol. 2009; 183(2): 937-944. doi: 10.4049/jimmunol.0804253.
- Alizadeh
D,
Trad
M,
Hanke
NT,
Larmonier
CB,
Janikashvili
N,
Bonnotte
B,
Katsanis
E,
Larmonier
N. Doxorubicin eliminates myeloid-derived suppressor cells and
enhances the efficacy of adoptive T-cell transfer in breast cancer.
Cancer Res. 2014;
74(1): 104-118. doi: 10.1158/0008-5472.CAN-13-1545.
- Xu
W,
Cai
J,
Li
S,
Zhang
H, Han
J, Wen M, Wen J, Gao F. Improving the in vivo persistence,
distribution and function of cytotoxic T lymphocytes by inhibiting the
tumor immunosuppressive microenvironment.
Scand
J Immunol. 2013; 78(1): 50-60. doi: 10.1111/sji.12065.
- Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the
comparative C(T) method. Nat Protoc 2008; 3: 1101-08. PMID: 18546601.
- Cheung
NK, Dyer
MA. Neuroblastoma:
developmental biology, cancer genomics and immunotherapy.
Nat Rev Cancer. 2013;
13(6): 397-411. doi: 10.1038/nrc3526.
- Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinate dregulation
of myeloid cells by tumors. Nat Rev Immunol. 2012; 12(4): 253-268.
doi: 10.1038/nri3175.
- Jordan
KR, Kapoor P, Spongberg E, Tobin RP, Gao D, Borges VF, McCarter MD.
Immunosuppressive myeloid-derived suppressor cells are increased in
splenocytes from cancer patients.
Cancer Immunol
Immunother. 2017; 66(4): 503-513. doi: 10.1007/s00262-016-1953-z.
- Solito
S, Pinton L, Mandruzzato S. In Brief: Myeloid-derived suppressor
cells in cancer. J
Pathol. 2017 Jan 18. [Epub ahead of print] doi:
10.1002/path.4876.
- Gabrilovich
DI. Myeloid-Derived suppressor cells.
Cancer Immunol
Res. 2017; 5(1): 3-8. doi: 10.1158/2326-6066.CIR-16-0297.
- Chen J, Ye Y, Liu P, Yu W, Wei F, Li H, Yu J.
Suppression of
T cells by myeloid-derived suppressor cells in cancer. Hum Immunol.
2017; 78(2): 113-119. doi: 10.1016/j.humimm.2016.12.001.
- Weiss
A, Littman
DR. Signal transduction by lymphocyte antigen receptors.
Cell. 1994; 76(2):
263-274. PMID: 8293463.
- Selleri
C, Maciejewski
JP, Catalano
L, Ricci
P, Andretta C, Luciano L, Rotoli B. Effects of cyclosporine on
hematopoietic and immune functions in patients with hypoplastic
myelodysplasia: in vitro and in vivo studies.
Cancer.
2002; 95(9): 1911-1922. doi:
10.1002/cncr.10915
- Hanson
EM, Clements
VK, Sinha P, Ilkovitch D, Ostrand-Rosenberg S. Myeloid-derived
suppressor cells down-regulate L-selectin expression on CD4+ and CD8+
Tcells.
J
Immunol. 2009; 183(2): 937-944. doi: 10.4049/jimmunol.0804253.
- Ostrand-Rosenberg
S. Myeloid-derived suppressor cells: more mechanisms for inhibiting
antitumor immunity.
Cancer
Immunol Immunother. 2010; 59(10): 1593-1600. doi:
10.1007/s00262-010-0855-8.
- Ku
AW, Muhitch
JB, Powers
CA, Diehl
M, Kim
M, Fisher
DT, Sharda
AP, Clements
VK, O’Loughlin K, Minderman H, Messmer
MN, Ma
J, Skitzki JJ, Steeber DA, Walcheck B, Ostrand-Rosenberg
S, Abrams
SI, Evans
SS. Tumor-induced MDSC act via remote control to inhibit
L-selectin-dependent adaptive immunity in lymph nodes.
Elife. 2016;
5. pii: e17375. doi: 10.7554/eLife.17375.
- Hassin
D,
Garber
OG,
Meiraz
A,
Schiffenbauer
YS, Berke G.
Cytotoxic T
lymphocyte perforin and Fas ligand working in concert even when Fas
ligand lytic action is still not detectable.
Immunology. 2011;
133(2): 190-196.
doi:10.1111/j.1365-2567.2011.03426.x
- Kim
JH,
Kang
TH,
Noh
KH,
Bae
HC, Kim
SH, Yoo YD, Seong
SY, Kim
TW. Enhancement of
dendritic cell-based vaccine potency by anti-apoptotic siRNAs
targeting key pro-apoptotic proteins in cytotoxic CD8(+) T
cell-mediated cell death.
Immunol Lett. 2009;
122(1): 58-67.
doi:10.1016/j.imlet.2008.12.006
- Martínez-Lostao
L, Anel A, Pardo J. How do cytotoxic lymphocytes kill cancer cells?
Clin Cancer Res.
2015; 21(22):5047-5056. doi: 10.1158/1078-0432.CCR-15-0685.
- Voskoboinik I, Whisstock JC, Trapani JA.
Perforin and
granzymes: function, dysfunction and human pathology. Nat Rev
Immunol. 2015; 15(6): 388-400.
doi:10.1038/nri3839
- Cullen
SP,
Brunet
M,
Martin
SJ. Granzymes in
cancer and immunity.
Cell Death Differ.
2010; 17(4): 616-623. doi:10.1038/cdd.2009.206.
- Alizadeh
D, Katsanis E, Larmonier N. Chemotherapeutic targeting of
myeloid-derived suppressor cells.
Oncoimmunology.
2014; 3(1): e27359. PMID: 24653963.
- Hsu
FT, Chen
TC, Chuang
HY, Chang
YF, Hwang
JJ. Enhancement of adoptive T cell transfer with single low dose
pretreatment of doxorubicin or paclitaxel in mice.
Oncotarget. 2015;
6(42): 44134-44150. doi: 10.18632/oncotarget.6628.